ME

23andMe Holding Co. Class A Common Stock

ME

Market cap $16.3M

Overview Fund Activity

Delisted

ME was delisted on the 28th of March, 2025.

Back to rankings

About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Employees: 582

Healthcare Drug Manufacturers - General

Financial journalist opinion

23andMe bankruptcy under congressional investigation for customer data

The House Committee on Energy and Commerce sent a letter to 23andMe expressing concern that its genetic data is "at risk of being compromised." The embattled genetic testing company filed for Chapter 11 bankruptcy protection in March, and its assets are up for sale.

23andMe bankruptcy under congressional investigation for customer data

US House committee seeks testimony from 23andMe co-founder after bankruptcy

A U.S. House committee on Monday asked 23andMe's co-founder to testify next month as it launched an investigation into the risk of genetic data being transferred to potential buyers amid the DNA testing company's bankruptcy.

US House committee seeks testimony from 23andMe co-founder after bankruptcy

23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors

Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.

23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors

Gulp Data Estimates 23andMe's Data Assets to Be Worth $289 Million Amid Bankruptcy Concerns

SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Gulp Data, a leader in data valuation and collateralization, estimates that the market comparable value of 23andMe's data assets is approximately $289 million. This valuation comes as concerns mount over the fate of the company's vast genetic database following its financial struggles. 23andMe, a pioneer in consumer genetic testing, has built an extensive dataset containing valuable genomic and health-related information. However, as recent reports highli.

Gulp Data Estimates 23andMe's Data Assets to Be Worth $289 Million Amid Bankruptcy Concerns

Bloomberg Markets and Finance

What's next for 23andMe and all that DNA data?

As 23AndMe files for bankruptcy, customers are left wondering what happens to their DNA data? On this episode of the Big Take podcast, we discuss what this means for millions of users' genetic data and for the future of the genetic testing industry.

What's next for 23andMe and all that DNA data?

US regulators tell 23andMe to protect genetic data

The US Federal Trade Commission (FTC) on Monday warned genetic testing firm 23andMe to honor its promise to protect people's personal information as it navigates bankruptcy.

US regulators tell 23andMe to protect genetic data

FTC concerned about privacy protections in 23andMe bankruptcy

Any purchaser of 23andMe assets should agree to be bound by the company's existing privacy policy, FTC Chairman Andrew Ferguson said.

FTC concerned about privacy protections in 23andMe bankruptcy

What users need to know about privacy and data after 23andMe's bankruptcy filing

23andMe, one of the first companies to provide direct-to-consumer genetic testing kits, has filed for bankruptcy. Since its founding in 2006, it has sold over 12 million DNA kits, with high-profile users including Oprah Winfrey and Warren Buffett.

What users need to know about privacy and data after 23andMe's bankruptcy filing

23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing

The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.

23andMe bankruptcy: With America's DNA put on sale, market panic gets a new form of testing

23andMe's failure shows how risky it can be to invest in a SPAC

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

23andMe's failure shows how risky it can be to invest in a SPAC

See News Rankings

Charts implemented using Lightweight Charts™